Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GH Research ( (GHRS) ) just unveiled an announcement.
On January 2, 2026, GH Research PLC announced that it plans to provide an update on the status of its Investigational New Drug Application (IND) for its lead candidate GH001 with the U.S. Food and Drug Administration, along with details on its global pivotal Phase 3 program in treatment-resistant depression, on January 5, 2026. The planned update signals a key regulatory and clinical development milestone for the company, as progress on GH001’s IND and Phase 3 program will be central to its efforts to bring a potential practice-changing treatment for TRD to market and could materially influence its position in the competitive depression therapeutics landscape.
The most recent analyst rating on (GHRS) stock is a Hold with a $12.50 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
The score is held down primarily by weak operating fundamentals (no revenue, expanding losses, and sustained cash burn). Technical indicators also point to weak momentum with price below key moving averages and a negative MACD. Offsetting factors are a low-debt, equity-supported balance sheet that reduces solvency risk, but valuation is constrained by negative earnings and no dividend data.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC is a Dublin-based clinical-stage biopharmaceutical company focused on developing novel mebufotenin-based therapies for depression, with an initial emphasis on treatment-resistant depression (TRD). Its lead product candidate, GH001, uses a proprietary inhalation delivery approach and has shown promising Phase 2b results, including a statistically significant reduction in MADRS depression scores compared with placebo in TRD patients.
Average Trading Volume: 303,237
Technical Sentiment Signal: Buy
Current Market Cap: $787.8M
Find detailed analytics on GHRS stock on TipRanks’ Stock Analysis page.